We sought to test whether one month of daily oral conjugated equine estrogen (CEE) or transdermal estradiol alters hemostatic factors in postmenopausal subjects. BACKGROUND Estrogen replacement therapy and hormonal replacement therapy (HRT) effect an early increase in cardiovascular events in postmenopausal women. Circulating plasma von Willebrand factor (vWF) antigen is a marker of generalized endothelial dysfunction and atherothrombosis.
Cardiovascular disease is the leading cause of mortality for women in the U.S. (1, 2) . The role of hormone replacement therapy (HRT) with estrogen and progesterone for primary and secondary prevention of coronary artery disease in women remains controversial. Observational studies have demonstrated that women who had used estrogenreplacement therapy (ERT) with or without progestins (i.e., HRT) during the menopausal years had a lower incidence of cardiovascular events, as compared with untreated women (3, 4) . Indeed, several potential mechanisms attributed to ERT or HRT had been considered to account for a beneficial effect. For example, oral exogenous estrogen increases the level of high-density lipoprotein (HDL) cholesterol and decreases the concentration of low-density lipoprotein (LDL). Moreover, several studies have suggested that ERT or HRT exerts a profibrinolytic effect by reducing plasminogen activator inhibitor-1 (PAI-1), the endogenous inhibitor of tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
However, recent studies have cast doubt on the cardioprotective effects of HRT. The secondary prevention trialthe Heart and Estrogen/progestin Replacement Study (HERS)-examined 2,763 subjects with proven coronary artery disease and randomized them to conjugated equineestrogen (CEE) with medroxyprogesterone acetate (MPA) or placebo (16) . Over a four-year period, there was no difference in the number of secondary cardiovascular events and adverse events from peripheral vascular disease between the HRT-treated subjects and the placebo-treated subjects (16) . The group receiving HRT experienced a 50% higher cardiac event rate during the first year (absolute excess of 1.4%) and a lower rate from the third year onward. The investigators considered that the results might be attributable to dual effects, such as an immediate prothrombotic, proarrhythmic, or proischemic effect that was later outweighed by slower progression of atherosclerosis. In further support of the lack of a benefit from HERS, the Estrogen Replacement and Atherosclerosis (ERA) trial demonstrated that three years of treatment with either CEE or CEE with MPA did not slow the rate of angiographic coronary artery disease progression, compared with placebo, in 309 postmenopausal women with established coronary artery disease (17) . The von Willebrand factor (vWF) has recently been proposed as a marker of generalized endothelial dysfunction, and as such, may contribute to the development of atherothrombotic disease (18, 19) . vWF is synthesized by the endothelium and megakaryocytes, and increased concentrations of vWF have been found in patients with peripheral vascular disease, cerebral vascular disease, and coronary artery disease (20 -22) . In addition, patients with known disease are at greater risk of cardiovascular mortality if they have high concentrations of vWF (21) (22) (23) (24) (25) . The Hoorn study of 631 patients demonstrated that increased vWF is independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic patients (26) .
We hypothesized that the early effects of treatment with oral CEE in postmenopausal women might increase markers associated with endothelial dysfunction, such as vWF. Therefore, we conducted a short-term study and measured the concentrations of vWF, lipids, and other hemostatic factors in postmenopausal subjects receiving daily oral CEE versus transdermal estradiol or placebo for one month. In this study, we demonstrate that one-month treatment with oral CEE, but not transdermal estradiol, significantly increases vWF, thereby potentially increasing the likelihood of cardiovascular events.
METHODS
The Institutional Review Board of the ColumbiaPresbyterian Medical Center approved the protocol, and written, informed consent was obtained from each subject, in accordance with institutional guidelines. Subjects who were postmenopausal for at least one year participated. Menopausal status was confirmed by measures of the estradiol concentration (Ͻ50 pg/ml) and folliclestimulating hormone (Ͼ20 mU/ml), consistent with menopause. No subject was currently taking or had previously taken ERT within the past year. Exclusion criteria included a personal or immediate family history of breast or endometrial cancer, previous myocardial infarction, coronary artery disease, thrombophlebitis or a history of thromboembolic disease, and a previous adverse reaction to estrogen. Only subjects with a normal mammogram within the year were enrolled. Subjects with an abnormal metabolic-renal profile, including hyperglycemia and hypercalcemia, were not enrolled.
Subjects underwent testing at baseline and after two and four weeks of therapy. At enrollment, each had a history and physical examination. Venous blood samples were collected during each visit. At baseline and after four weeks, blood was collected for a complete blood count, chemicalmetabolic profile-including electrolytes, hepatic and renal function, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, estradiol, follicle-stimulating hormone, progesterone, luteinizing hormone-and urinalysis, as well as t-PA antigen, PAI-1 antigen, fibrin D-dimer, vWF antigen, and fibrinogen. After two weeks, blood was also collected for hormonal and hemostatic factors to assess patient compliance. Subjects were entered into a randomized, double-blind, placebo-controlled trial using one of two forms of hormonal replacement: oral CEE (Premarin), 0.625 mg/day, or transdermal estrogen (Climara), 0.1 mg/day. Because concurrent progestins given in conjunction with CEE may offset estrogenic effects, we elected to treat subjects with estrogen monotherapy. Subjects were randomized by means of a random table to three groups in a ratio of 2:1:1, as to whether they received oral CEE, transdermal estrogen, or oral placebo, respectively. The rationale for the randomization scheme, which favored oral administration, was the consideration that the majority of women prescribed postmenopausal ERT use CEE.
There were 55 subjects enrolled: 48 were randomized, and 38 completed the trial. Three subjects randomized to oral CEE did not complete the study because of stomach upset (n ϭ 1) or noncompliance (n ϭ 2). Three subjects randomized to transdermal estrogen did not complete the study because of vaginal bleeding (n ϭ 1), noncompliance (n ϭ 1), and elective withdrawal (n ϭ 1). Four randomized to placebo did not complete the study because of migraine headache (n ϭ 1), noncompliance (n ϭ 1), a hormone concentration that did not meet entry criteria for menopause (n ϭ 1), and generalized discomfort following medication (n ϭ 1). Thirty-eight postmenopausal subjects completed the study. The subjects (average age 59 Ϯ 7 years) received daily oral CEE, 0.625 mg (n ϭ 21); transdermal estradiol, 0.1 mg/day (n ϭ 7); or oral placebo (n ϭ 10) for one month.
Plasma samples were collected before and after treatment in the morning, at the same time of the day for each visit. Blood samples were drawn at rest from a large antecubital vein into 0.1 mol/liter trisodium citrate tubes for analysis of t-PA antigen, PAI-1 antigen, fibrin D-dimer antigen, and vWF. The tubes were immediately centrifuged and spun at 3,000g for 20 min at 4°C. This centrifugation was performed within 1 h. The plasma was removed into aliquots and stored at Ϫ80°C for up to four months before analysis. The assays for PAI-1, t-PA, and vWF were determined using the respective enzyme-linked immunosorbent assay (ELISA) kits purchased from American Diagnostics, Inc. (Greenwich, Connecticut). The t-PA antigen measured by ELISA was the total amount of t-PA present (free and complexed t-PA, single-chain and double-chain t-PA) (27 quantity of PAI-1 present (free or complexed with t-PA; active or inactive form) (27) . Fibrin D-dimer was analyzed using the Asserachrom D-Di ELISA from Diagnostica Stago (Asnieres-Sur-Seine, France). Estradiol, progesterone, follicle-stimulating hormone, and luteinizing hormone concentrations were determined by their specific immunoassays from Diagnostic Products Corp. (Los Angeles, California), according to the manufacturer's instructions. Interassay coefficient of variation for estradiol at high, middle, and low control concentrations are 3.5%, 4.6%, and 9.6%, respectively. Total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and fibrinogen concentrations were determined by conventional enzymatic methods. Statistical analysis. Data on baseline characteristics were analyzed by ANOVA, with post-hoc differences in mean values among groups assessed using Tukey's procedure. Statistical significance was defined as a two-sided p value Ͻ0.05. The effect of estrogen within each group on hormones and lipid concentrations was determined using a two-tailed, paired Student t test. In addition, to correct for individual differences in baseline values among subjects, relative changes in the effect of estrogen treatment within each group on hormones, lipids, and hemostatic factor concentrations were assessed using a log-transform of the various factors. Table 1 shows the baseline characteristics of the assigned subjects. There were no significant differences among the placebo, oral CEE, and transdermal estradiol groups at baseline. Table 2 shows the effect of oral CEE and transdermal estradiol therapy on hormones and lipids after one month. Subjects assigned to oral CEE experienced a significant increase in estradiol (p Ͻ 0.01) and a decrease in folliclestimulating hormone from baseline to four weeks (p Ͻ 0.01). Transdermal estradiol users experienced a nonsignificant increase in estradiol (p ϭ NS) and a significant decrease in follicle-stimulating hormone at four weeks (p Ͻ 0.01). Subjects assigned to oral CEE experienced a significant decrease in total cholesterol (p Ͻ 0.01) and LDL cholesterol (p Ͻ 0.01) and an increase in triglycerides (p Ͻ 0.05) and HDL cholesterol (p Ͻ 0.01). Neither transdermal estradiol nor placebo had a significant effect on lipids. Table 3 and Figure 1 show the effect of oral CEE and transdermal estradiol on hemostatic factors; there was no effect of placebo on hemostatic factors. For the subjects randomized to oral CEE and transdermal estradiol, PAI-1 (ng/ml) declined, but it achieved only borderline significance (p Ͻ 0.08), and only in the oral CEE subjects. There was a significant decrease in t-PA antigen (p Ͻ 0.004) after oral CEE. Fibrin D-dimer did not vary significantly in any group. However, oral CEE users experienced a significant increase (p Ͻ 0.03) in vWF from baseline to four weeks, which was significantly different from the change observed in the transdermal estradiol group. Neither oral CEE nor transdermal estradiol had significant effects on fibrinogen.
RESULTS
The change observed for t-PA in the oral CEE group was significantly different from that observed in the transdermal group (p Ͻ 0.05) and that in the placebo group (p Ͻ 0.05). Subjects using placebo experienced no significant change in any hormone, lipid, or hemostatic factor values from baseline to two and four weeks. 
Data are presented as the mean value Ϯ SD. CEE ϭ conjugated equine estrogen; HDL ϭ high-density lipoprotein; LDL ϭ low-density lipoprotein. (28) . Most of the t-PA in the plasma travels while bound to PAI-1 molecules to form circulating, inactive t-PA/PAI-1 com- plexes (29, 30) . Therefore, oral CEE-induced decreased t-PA and PAI-1 antigen levels may reflect diminished t-PA/PAI-1 complexes and, hence, augmented fibrinolytic activity. Recent studies have suggested that increased circulating vWF antigen denotes a poor prognosis in unstable angina and non-ST-segment elevation myocardial infarction (31) . Moreover, patients undergoing percutaneous coronary interventions who have unstable angina have higher vWF antigen levels than do patients with stable angina, and the decrease in vWF antigen after a successful percutaneous intervention may reflect plaque re-endothelialization and stabilization (32) . Indeed, vWF facilitates platelet aggregation at sites of vascular injury under high shear stress, and elevated plasma vWF antigen concentrations correlate with enhanced platelet adhesion to collagen types I, III, and IV-all extremely potent physiologic inducers of platelet aggregation at the site of plaque rupture and vascular injury (33) . Studies with vWF-deficient mice indicate that the absence of vWF predominantly affects aortic regions with disturbed flow that are prone to atherosclerosis (34) . vWF may recruit platelets and leukocytes to the lesion in a flow-dependent fashion or may be part of the mechanotransduction pathway that regulates the endothelium's response to shear stress (34) .
Therefore, the oral CEE-mediated increase of vWF antigen at one month in our study may partially explain the results of HERS, which found an early increase in cardiovascular events after oral CEE and MPA. It should be noted that van Baal et al. (35) found a 14% decrease in vWF in 14 healthy postmenopausal subjects after three months of oral CEE. Cushman et al. (36) found no effect of four different estrogen/progestin hormone preparations on vWF antigen levels in 365 patients after 12 months. One study measured the effect of oral CEE and transdermal estrogen after one month; however, in that study, vWF was not measured (5) . In a study by Lip et al. (37) , 27 premenopausal women (average age 43.6 years) received CEE, 0.625 mg, following a hysterectomy and bilateral salpingo-oophorectomy. They found a decrease in plasma levels of both vWF and t-PA after six weeks of CEE (37) . In contrast to the subjects described here, no subjects were naturally postmenopausal for at least one year; all had surgically induced menopause; all were considerably younger (as expected of a premenopausal population); and all had vasomotor symptoms. Furthermore, the investigators acknowledge that stress and blood loss, a consequence of surgery versus naturally occurring menopause, might have accounted for the findings.
The opportunity to evaluate the effects of CEE and transdermal estradiol after one month may provide insight into the time course of variables affected by estrogen. Although there are a considerable number of reports documenting estrogen's effect on markers of fibrinolysis and hemostasis, the results are not uniform. Tables 4 and 5 summarize the existing, sometimes contradictory, findings of 20 studies (5,10 -13,15,35,36,38 -49) . From this summary, we conclude that variability in the findings could be related to study design: estrogen formulations (e.g., CEE, estradiol valerate, micronized estradiol, 17-beta-estradiol), the size of dose, the method of estrogen replacement (e.g., cyclical, continuous), monotherapy or combination with progestin, the age of subjects, the time since the start of menopause, the duration of treatment, and the time of sampling. Although there are several reports relating the effect of ERT and HRT on PAI-1, few measured vWF. No other study measured vWF at one month, but more likely measured it at 3 to 4, 6, 12, and 36 months. Two studies collected samples as early as three months; however, one used micronized estradiol plus 1 or 2 mg dydrogesterone (35) and found that vWF decreased, and the other used CEE plus 5 mg medrogestone (12) and found no effect on vWF.
Thus, it is possible that oral CEE exerts very early effects, increasing vWF antigen after one month, which may then dissipate over time with no effects found on vWF levels by three months to one year. We found that one month of transdermal estradiol had no effect on vWF antigen levels, a finding consistent with the results of a study of transdermal estradiol in 28 postmenopausal hysterectomized subjects after four months of therapy (42) .
Our finding that oral, but not transdermal, estrogen increases plasma vWF antigen after one month of therapy is noteworthy in that vWF is not only a marker of endothelial dysfunction and enhanced atherothrombotic activity, but also is a marker of inflammation (36, 41) . In this regard, recent reports have discovered that HRT initially increases levels of C-reactive protein (CRP), an inflammatory marker that is a potent prognosticator of an increased risk of cardiovascular events in both women and men (36, 37, 42, 50) . Indeed, HRT appears to increase high-sensitivity CRP within four to eight months of the initiation of therapy. Therefore, oral CEE may cause an early increase in both inflammation and hemostasis, as evidenced by early elevations in both vWF and CRP, which result in an early increase in cardiovascular events. Furthermore, our findings that oral CEE, but not transdermal estradiol, induced the aforementioned effects is intriguing considering that the proinflammatory cytokine, interleukin-6, which is the primary stimulant of hepatic CRP (51) , is also a potent inducer of vWF (52) .
Oral CEE increased HDL cholesterol and decreased LDL cholesterol and total cholesterol, even in subjects who were overweight (Table 2) , which corresponds to previous studies demonstrating that oral CEE has beneficial effects on the lipid profile (53, 54) . However, we also found that oral CEE concomitantly increases triglycerides, as evidenced by previous studies (53, 54) . In addition, it should be noted that, despite decreasing total cholesterol and LDL cholesterol, oral CEE actually decreases the LDL particle size, increases the very low density lipoprotein size, and only minimally reduces the concentration of apolipoprotein B (53,54). Furthermore, our study demonstrates that trans-1995 JACC Vol. 40, No. 11, 2002 Rabbani et al. December 4, 2002 December 4, :1991 Oral Estrogen Increases vWF 2 ϭ decrease after estrogen; 1 ϭ increase after estrogen; -ϭ level not reported; NS ϭ not significant; other abbreviations as in Table 3 .
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